The history of copyright's flagship drug presents a nuanced case for investors in the medicinal sector. While initially a tremendous success, producing vast sums, the patent lapse and the subsequent entry of generic alternatives have drastically changed revenue. This poses questions about the future profitability of analogous therapeutic projects a